Loading clinical trials...
Loading clinical trials...
A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma
Conditions
Interventions
Ibrutinib
Paclitaxel
+1 more
Locations
2
United States
University of California, San Francisco
San Francisco, California, United States
Oregon Health and Science University
Portland, Oregon, United States
Start Date
October 12, 2015
Primary Completion Date
November 15, 2019
Completion Date
September 1, 2020
Last Updated
May 6, 2021
NCT07409272
NCT06998940
NCT06381154
NCT07226856
NCT07344220
NCT01660971
Lead Sponsor
Margaret Tempero
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions